INTRODUCTION
============

Epidermal growth factor receptor (EGFR) signaling regulates many cellular processes, most notably cell proliferation in mammalian cells ([@B26]). Thus it is not surprising that EGFR and family members are overexpressed in many human cancers. Lysosomal degradation is an important mechanism to turnover activated EGFR ([@B34]). On activation, EGFR is internalized into early endosomes, where the cytoplasmic tail is still able to engage downstream signaling proteins. Maturation of early endosomes into late endosomes is accompanied by the formation of multivesicular bodies and the internalization of EGFR from the outer membrane into intraluminal vesicles and thus sequestration of EGFR from downstream signaling proteins. Subsequent fusion with lysosomes results in the ultimate destruction of EGFR. Rab GTPases are important mediators of endosome trafficking ([@B35]). The coordinated functions of the Rab5 and Rab7 GTPases regulate early-to-late endosome maturation and lysosomal fusion. Inhibition of Rab7 in mammalian cells results in accumulation of EGFR in multivesicular bodies and in both *Caenorhabditis elegans* and mammalian cells leads to increased EGFR signaling ([@B41]; [@B33]; [@B6]). In addition to mediating late endosome fusion with lysosomes along with the HOPS complex, Rab7 couples with the dynein minus-end microtubule motor via the Rab7-interacting proteins RILP and ORP1L, which tether to the dynactin complex, a regulator of dynein ([@B19]). Inhibition of dynactin by overexpression of the p50 subunit blocks endosome movement from the cell periphery, inhibits EGFR degradation, and causes sustained Erk1/2 activation ([@B40]). However, dynein can be recruited by other Rab GTPases to mediate membrane trafficking in the endocytic and secretory pathways ([@B15]; [@B16]). In *Drosophila*, dynein promotes EGFR signaling during eye and wing development by promoting secretion of the EGFR ligand, Spitz ([@B18]). Thus dynein has both positive and negative effects on EGFR signaling in fruit fly and mammalian tissue culture cells, respectively.

*C. elegans* vulva development provides an in vivo model to study EGFR signaling in epithelial cells ([@B37]; [@B30]). During larval development, six vulval precursor cells (VPCs), P3.p--P8.p, express LET-23 EGFR on both the apical and basolateral membranes. The anchor cell in the overlying gonad secretes an EGF-like ligand, LIN-3, which engages LET-23 EGFR on the basolateral membrane, initiating a conserved Ras/mitogen-activated protein kinase (MAPK) signaling pathway in the P6.p cell and specifying the primary vulval cell fate. Graded LIN-3 signaling and LIN-12 Notch signaling specify the neighboring P5.p and P7.p cells to adopt the secondary vulval fates. P5.p--P7.p cells undergo three rounds of cell division to generate the 22 cells of the mature vulva. The remaining uninduced VPCs (P3.p, P4.p, and P8.p) divide once (P3.p does not divide 50% of the time) and fuse with the surrounding hypodermis. Mutations that decrease LET-23 EGFR signaling result in a vulvaless (Vul) phenotype in which fewer than three VPCs are induced. Mutations that increase LET-23 EGFR signaling result in a multivulva (Muv) phenotype in which more than three VPCs are induced. The LIN-2 Cask/LIN-7 Veli/LIN-10 Mint (LIN-2/7/10) complex binds the C-terminal tail of LET-23 EGFR and is required for the basolateral localization of LET-23 EGFR in the VPCs and vulva induction. Mutations in the *lin-2/7/10* complex result in primarily apical localization of LET-23 EGFR and a strong Vul phenotype.

In a suppressor screen of the *lin-2* mutant Vul phenotype, we identified two suppressors with embryonic lethal phenotypes, *vh4* and *vh22* ([@B32]). We previously reported that *vh4* is a mutation in the *agef-1* gene that partially restores basolateral membrane localization of LET-23 EGFR. Here we report that *vh22* is a temperature-sensitive mutation in *dhc-1*, the heavy chain of the dynein minus end--directed microtubule motor. We demonstrate that *dhc-1* is a strong negative regulator of LET-23 EGFR signaling that functions upstream of or in parallel to LET-23 EGFR. LET-23::GFP accumulates in foci in the P6.p descendants of *dhc-1(vh22)* animals, consistent with a defect in endocytic trafficking of LET-23 EGFR. Unlike *rab-7* mutants, many of the LET-23::GFP foci in *dhc-1(vh22)* mutants remain adjacent to the plasma membrane, suggesting that *dhc-1* regulates an earlier step of LET-23 EGFR trafficking to the lysosome.

RESULTS
=======

Identification of *vh22* as an essential suppressor of the *lin-2(-)* Vul phenotype
-----------------------------------------------------------------------------------

Mutations in the *lin-2*, *lin-*7, or *lin-10* gene result in a strong Vul phenotype that is easily suppressed by loss of a negative regulator of LET-23 EGFR signaling, such as the SLI-1 Cbl E3 ubiquitin ligase homologue, the GAP-1 Ras GAP, or the LIP-1 MAPK phosphatase ([@B20]; [@B43]; [@B13]; [@B7]). We previously identified the *rab-7(ok511)* deletion as a strong suppressor of mutations in the *lin-2, lin-7*, and *lin-10* genes, reverting a strong Vul phenotype back to wild-type and Muv phenotypes ([@B33]). The maternal effect embryonic lethality of the *rab-7(ok511)* mutation would preclude its identification in screens for viable suppressors. Therefore we conducted a clonal forward genetic screen for essential suppressors of the *lin-2(e1309)* Vul phenotype to identify additional genes that might function with *rab-7* to antagonize LET-23 EGFR signaling ([@B32]). We identified the *vh22* mutation as a strong suppressor of the *lin-2(e1309)* Vul phenotype. Whereas *lin-2(e1309)* mutants are 100% Vul, the *vh22; lin-2(e1309)* double mutants are only 15% Vul at 20°C, with 85% of the animals developing a wild-type vulva ([Figure 1, A--D](#F1){ref-type="fig"}, and [Table 1](#T1){ref-type="table"}). Like mutations in other negative regulators, *vh22* single mutants have essentially normal vulva induction ([Figure 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). In addition, *vh22* animals are ∼80% embryonic lethal at 20°C and have a small-body morphology phenotype ([Table 2](#T2){ref-type="table"}; unpublished data). Embryos often arrest with undifferentiated multinucleate cells, indicative of an early cell division defect ([Figure 1, E and D](#F1){ref-type="fig"}). However, no cell division defects were observed in the vulval cell lineages. The embryonic lethality and the suppression of the *lin-2(e1309)* Vul phenotypes were temperature sensitive, as both phenotypes were considerably less severe at 15°C and more severe at 25°C ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

![*dhc-1(vh22)* suppresses the *lin-2(e1309)* Vul phenotype. (A--D) Representative DIC images of vulvas of wild-type, *lin-2(e1309)*, *dhc-1(vh22)*, and *dhc-1(vh22); lin-2(e1309)* L4-stage larvae. The *lin-2(e1309)* larva lacks a vulva, whereas in *dhc-1(vh22); lin-2(e1309)*, the vulva is mostly restored. *dhc-1(vh22)* single mutants have a wild-type vulva. (E--G) DIC images of early embryos of wild-type, *dhc-1(vh22)*, and *dhc-1(or195).* Bars, 10 μm.](3771fig1){#F1}

###### 

Loss of *dhc-1* suppresses the *lin-2(e1309)* Vul phenotypes.

  Genotype                                            Temperature(°C)   Muv(%)   Vul (%)    Average number of VPCs induced   Number of animals scored
  --------------------------------------------------- ----------------- -------- ---------- -------------------------------- --------------------------
  Wild type                                           All               0        0          3.0                              Many
  *dhc-1(vh22)*                                       20                0        5          2.98                             20
  *lin-2(e1309)*                                      20                0        100        0.29                             21
  *dhc-1(vh22); lin-2(e1309)*                         15                5        80\*\*     1.5\*\*\*                        20
                                                      20                0        15\*\*\*   2.85\*\*\*                       20
                                                      25                0        11\*\*\*   2.98\*\*\*                       20
  *GFP(RNAi); dhc-1(vh22); lin-2(e1309)*              20                12       24         2.82                             25
  *dhc-1(RNAi); dhc-1(vh22); lin-2(e1309)*            20                4        8          2.94                             25
  *dhc-1(vh22); lin-2(e1309); orIs17\[GFP::DHC-1\]*   15                0        100\*      0.44                             26
                                                      20                12       58\*\*\*   1.80\*\*\*\*                     33
  *dhc-1(or195); lin-2(e1309)*                        15                0        100        0.13                             15
                                                      20                0        96         0.78\*\*                         23
                                                      25                0        89\*\*     0.9\*\*                          29
  *dhc-1(or352); lin-2(e1309)*                        15                0        100        0.23                             15
                                                      20                0        88\*\*     0.69\*\*                         18
                                                      25                0        76\*\*     1.53\*\*\*                       44
  *GFP(RNAi); lin-2(e1309)*                           20                0        100        0.32                             31
  *dhc-1(RNAi); lin-2(e1309)*                         20                7        85\*       1.59\*\*\*\*                     17
  *elpc-1(RNAi); lin-2(e1309)*                        20                0        95         0.36                             40
  *cpd-1(RNAi); lin-2(e1309)*                         20                0        98         0.3                              40

Statistical significance was determined using Fisher's exact test (graphpad.com/quickcalcs). *\*p* \< 0.05, *\*\*p* \< 0.01, *\*\*\*p* \< 0.001, *\*\*\*\*p* \< 0.0001. *dhc-1; lin-2* mutants were compared with *lin-2* single mutants. *orIs17*-carrying strains were compared with *dhc-1(vh22); lin-2(e1309)* at the same temperatures. *dhc-1(RNAi)*, *elpc-1(RNAi)*, and *cpd-1(RNAi)* were compared with *gfp(RNAi).* The penetrance of the *lin-2(e1309)* phenotype is similar at all temperatures.

###### 

*dhc-1(vh22)* is temperature-sensitive embryonic lethal.

                                      Percentage embryonic lethality (*n*)                       
  ----------------------------------- -------------------------------------- ------------------- -------------------
  *dhc-1(vh22)*                       23 (211)                               81 (274)            96 (126)
  *dhc-1(or195)*                      22 (369)                               97 (514)            99 (304)
  *dhc-1(or352)*                      26 (507)                               90 (460)            97 (934)
  *dhc-1(vh22)/dhc-1(or195)*                                                 96 (1218)           
  *dhc-1(vh22)/dhc-1(or352)*                                                 95 (1167)           
  *dhc-1(vh22); orIs17(DHC-1::GFP)*   1.3 (382)\*\*\*\*                      0.5 (583)\*\*\*\*   2.3 (264)\*\*\*\*

Statistical analysis was performed as in [Table 1](#T1){ref-type="table"}. The *dhc-1(vh22); orIs17* strain has the *lin-2(e1309)* mutation in the background and was compared to *dhc-1(vh22)* single mutants at the same temperature. *n*, number of embryos scored.

*vh22* is an allele of *dhc-1*
------------------------------

To identify the gene mutated by *vh22*, we used the associated small-body morphology and embryonic lethal phenotypes to map *vh22.* First, we found that *vh22* was balanced by the *hT2* balancer consisting of a translocation between chromosomes I and III ([@B44]). Single nucleotide polymorphism (SNP) mapping located *vh22* between SNPs *W03D8* at −6 map units (mu) and *pkP1057* at 1 mu on chromosome I ([Figure 2A](#F2){ref-type="fig"}). The location was further delineated by complementation with chromosomal deficiencies: *vh22* complemented *qDf3* and *mnDf111* but failed to complement *sDf4* and *hDf6*, indicating that *vh22* was located between −2.21 and 0.1 mu ([Figure 2A](#F2){ref-type="fig"}). Whole-genome sequencing identified two missense mutations in the *dhc-1* gene, which was previously reported to have early cell division defects ([Figure 1G](#F1){ref-type="fig"}; [@B11]; [@B31]), as well as homozygous nonsynonymous mutations in the *elpc-1* and *cpd-1* genes (see *Materials and Methods*). We found that RNA interference (RNAi) of *dhc-1* but not *elpc-1* or *cpd-1* significantly suppressed the *lin-2(e1309)* Vul phenotype ([Table 1](#T1){ref-type="table"}). *dhc-1(RNAi)* did not enhance or suppress the *vh22; lin-2(e1309)* vulval phenotype ([Table 1](#T1){ref-type="table"}). Consistent with *vh22* being a mutation in *dhc-1*, two conditional alleles of *dhc-1---or195* and *or352---*suppressed the *lin-2(e1309)* Vul phenotype at nonpermissive temperature ([Table 1](#T1){ref-type="table"}; [@B14]). Furthermore, *vh22* fails to complement *dhc-1(or195)* and *dhc-1(or352)* for the embryonic lethal phenotype ([Table 2](#T2){ref-type="table"}). Finally, we can rescue the *vh22* embryonic lethality and suppression of *lin-2(e1309)* Vul phenotype with a green fluorescent protein (GFP)::dynein heavy chain-1 (DHC-1) transgene, *orIs17* ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}; [@B10]). Therefore we conclude that *vh22* is a loss-of-function mutation in *dhc-1.*

![*dhc-1(vh22)* mapping and the lesions. (A) Schematic representation of the middle of chromosome I (LGI). The SNPs used for interval mapping are indicated on top with their chromosomal locations (map units \[mu\]). The number of recombinant animals positive for the Hawaiian SNP out of the total number of animals tested for each SNP is indicated below. The two chromosomal deficiencies that fail to complement *vh22*---*sDf4* and *hDf6*---are shown in red, and the complementing deficiencies---*qDf3* and *mnDf111*---are shown in blue. A bracket indicates the 2.1-mu interval between the left end of *hDf6* and the right end of *sDf4* to which *vh22* maps. (B) Homology domains of the DHC-1 protein in common with the dynein heavy chains from other organisms: dimerization and accessory chain interaction domains (DHC_1 and DHC_2) in blue, AAA-type ATPase domains (AAA1--6) in red, and the microtubule-binding stalk (MT binding) in green. The locations of the two missense mutations in *vh22* and the *or195* and *or352* alleles are shown below. Valine 3228 in the microtubule-binding stalk is changed to an aspartic acid. Valine 3228 in *C. elegans* (*Cel*) is conserved in *D. melanogaster* (*Dme*) NP_001261430.1, *Homo sapiens* (*Hsp*) NP_0011367.2, and *Strongylocentrotus purpuratus* (*Spu*) XP_797645.3 but not in the fungi *Aspergillus nidulans* (*Ani*) XP_657722.1, *Schizosaccharomyces pombe* (*Spo*) XP_001713108.1, or *Saccharomyces cerevisiae* (*Sce*) GAA24775.1. Aspartic acid 4344 resides in a C-terminal region and is changed to an asparagine. Aspartic acid 4344 and the surrounding region are conserved among the metazoans analyzed but not present in the fungi. Amino acid (aa) identities are highlighted in black and similarities in gray.](3771fig2){#F2}

DHC-1 is the *C. elegans* dynein heavy chain subunit of the cytoplasmic dynein complex, a minus end--directed microtubule motor ([@B25]). DHC-1 comprises the motor and microtubule-binding domain (C-terminal half) and a stem (N-terminal) that is involved in dimerization and recruitment of numerous accessory chains and regulators ([Figure 2B](#F2){ref-type="fig"}; [@B1]). The missense mutations in *dhc-1* change two amino acid residues that are conserved in metazoans but not fungi. The first mutation changes a valine 3228 to an aspartic acid in the microtubule-binding domain, the second, an aspartic acid 4344 to asparagine in a metazoan-specific C-terminal domain. We do not know which change or whether both changes contribute to the *dhc-1(vh22)* phenotypes, but *vh22* is a stronger suppressor of the *lin-2(-)* Vul phenotype than the *or195* and *or352* alleles, which have been deemed strong mutations with respect to embryonic phenotypes ([Table 1](#T1){ref-type="table"}; [@B31]).

*dhc-1* functions upstream or in parallel to *let-23 EGFR*
----------------------------------------------------------

Suppression of the *lin-2(e1309)* Vul phenotype by *dhc-1* alleles suggests that DHC-1 is a negative regulator of LET-23 EGFR signaling. Consistent with this hypothesis, we find that *dhc-1(vh22)* enhances the Muv phenotype of a gain-of-function mutation in *let-60 Ras, n1046* ([Table 3](#T3){ref-type="table"}). The *let-23(sy1)* allele truncates the last six amino acids shown to be required for binding the LIN-2/7/10 complex and thus has an identical vulval phenotype as mutations in *lin-2/7/10* ([@B3]; [@B21]). We find that *dhc-1(vh22)* strongly suppresses the Vul phenotype of the *let-23(sy1)* and *lin-7(e1413)* mutations and that *dhc-1(RNAi)* suppresses the Vul phenotype of the *lin-10(e1439)* mutation ([Table 3](#T3){ref-type="table"}). The *let-23(sy97)* mutation is a more severe truncation of LET-23 EGFR, which blocks signaling to LET-60 Ras in multiple tissues ([@B4]). We find that *dhc-1(vh22)* fails to suppress the Vul phenotype of *let-23(sy97)*, consistent with *dhc-1* functioning upstream or in parallel to *let-23 EGFR* ([Table 3](#T3){ref-type="table"}). *lin-3(e1417)* is a strong hypomorphic mutation in the promoter of *lin-3 EGF* that specifically abrogates *lin-3 EGF* expression in the Anchor Cell ([@B17]). We find that *dhc-1(vh22)* significantly suppresses the Vul phenotype of *lin-3(e1417)*, suggesting that *dhc-1* functions downstream of or in parallel to *lin-3 EGF* ([Table 3](#T3){ref-type="table"}). Taken together, these data suggest that DHC-1 is genetically a negative regulator of LET-23 EGFR signaling and functions at the level of LET-23 EGFR.

###### 

DHC-1 negatively regulates LET-23 EGFR signaling downstream or in parallel to LIN-3 EGF.

  Genotype                       Muv (%)   Vul (%)      Average number of VPCs induced   Number of animals scored
  ------------------------------ --------- ------------ -------------------------------- --------------------------
  *let-60(n1046)*^a^             65        0            3.55                             20
  *dhc-1(vh22); let-60(n1046)*   92        0            4.18\*\*                         24
  *lin-7(e1413)*                 0         92           0.28                             36
  *dhc-1(vh22); lin-7(e1413)*    5         38\*\*\*\*   2.5\*\*\*\*                      42
  *GFP(RNAi); lin-10(e1439)*     0         95           0.31                             85
  *dhc-1(RNAi); lin-10(e1439)*   0         91           0.69\*\*\*                       90
  *let-23(sy1)*                  0         100          0.06                             25
  *dhc-1(vh22); let-23(sy1)*     3         57\*\*\*\*   1.79\*\*\*\*                     35
  *let-23(sy97)*^a^              0         93           0.4                              29
  *dhc-1(vh22); let-23(sy97)*    0         100          0.24                             23
  *lin-3(e1417)*                 0         92           0.94                             36
  *dhc-1(vh22); lin-3(e1417)*    0         82           1.56\*\*\*                       50

Statistical analysis was done as in [Table 1](#T1){ref-type="table"}. Experiments were performed at 20°C.

^a^Control data were previously published, as they were collected together with both *agef-1(vh4)* ([@B32]) and *dhc-1(vh22)* double-mutant strains.

DHC-1 functions in the VPCs to negatively regulate LET-23 EGFR signaling
------------------------------------------------------------------------

If DHC-1 is regulating LET-23 EGFR, then we anticipated that DHC-1 would function in the VPCs, the signal-receiving cells. To determine whether DHC-1 negatively regulates signaling in the signal-receiving cells, we performed *dhc-1(RNAi)* specifically in the VPCs. We took advantage of the tissue-specific rescue of *rde-1(ne219)* mutant animals, which are deficient for RDE-1, an Argonaute required for exogenous RNAi ([@B38]; [@B28]). Expression of wild-type *rde-1(+)* under the VPC-specific promoter *lin-31* (*mfIs70)* in the *rde-1(ne219)* mutant confers sensitivity to RNAi specifically in the VPCs ([@B39]; [@B5]). *rde-1(ne219); lin-2(e1309)* double mutants expressing *rde-1(+)* in the VPCs were fed RNAi for *GFP*, *dhc-1*, and *rab-7*. Consistent with our previous findings in the whole-animal RNAi experiments, depletion of either *dhc-1* or *rab-7* by RNAi specifically in the VPCs partially suppressed the *lin-2* Vul phenotype, whereas RNAi targeting GFP did not ([Table 4](#T4){ref-type="table"}). These data are consistent with both DHC-1 and RAB-7 functioning in the VPCs to negatively regulate EGFR signaling.

###### 

DHC-1 functions in the VPCs.

  RNAi      Muv (%)   Vul (%)   Average number of VPCs induced   Number of animals scored
  --------- --------- --------- -------------------------------- --------------------------
  *GFP*     0         100       0.09                             48
  *dhc-1*   0         98        0.44\*\*\*                       50
  *rab-7*   2         98        0.33\*\*                         46

The strain QR405: *rde-1(ne219); mfIs70\[Plin-31::RDE-1\]; lin-2(e1309)* was used for VPC-specific RNAi feeding. Statistical analysis was done as in [Table 1](#T1){ref-type="table"}. Experiments were performed at 20°C.

DHC-1 and RAB-7 regulate LET-23 EGFR trafficking
------------------------------------------------

We previously found that RAB-7 regulates the localization of LET-23 EGFR in the VPCs ([@B33]). Specifically, the *rab-7(ok511)* deletion results in the accumulation of cytoplasmic LET-23::GFP foci in the VPCs of wild type and *lin-2(e1309)* mutants expressing the *gaIs27* LET-23::GFP transgene. However, this transgene did not show the expected localization of LET-23::GFP at the basolateral membrane, which kept us from determining whether RAB-7 regulates apical versus basolateral localization. We reassessed the role of RAB-7 in the regulation of LET-23 EGFR trafficking in the VPCs of live animals using a new LET-23::GFP transgene, *zhIs038*, which expresses at levels comparable to endogenous LET-23 EGFR and shows clear localization at the basolateral membrane in wild-type VPCs but not *lin-2(e1309)* mutants ([Figure 3, A and B](#F3){ref-type="fig"}; [@B12]). The *rab-7(ok511)* mutation had a small effect on LET-23::GFP localization in the P6.p cell (Supplemental Figure S1). However, the daughter cells, P6.pa and P6.pp, showed a robust accumulation of LET-23::GFP foci in *rab-7(ok511)* and *rab-7(ok511); lin-2(e1309)* mutants ([Figure 3, C, D, I, and J](#F3){ref-type="fig"}). This confirms our previous data with the *gaIs27* transgene and is consistent with RAB-7 being required for LET-23 EGFR trafficking to lysosomes ([@B33]).

![DHC-1 and RAB-7 differentially regulate LET-23 EGFR trafficking. (A--H) Represen­tative confocal images of LET-23::GFP localization in the P6.p daughter cells---P6.pa and P6.pp---of *zhIs038* transgene-carrying animals. The receptor is localized to both basolateral and apical membranes of wild-type animals (A) but is restricted to the apical membrane in *lin-2(e1309)* animals (B). *rab-7(ok511)* and *dhc-1(vh22)* mutants accumulate LET-23::GFP in the punctate structures within the vulval cells (C, D) and adjacent to the plasma membrane (E, F), respectively, in both wild-type (C, E) and *lin-2(e1309)* backgrounds. (G) *dhc-1(or195)* mutants also accumulate LET-23::GFP foci at 25°C. (H) *dhc-1(RNAi)* does not significantly change the *dhc-1(vh22); lin-2(e1309)* phenotype. (I, J) Box-and-whiskers plots of the number of LET-23::GFP foci in the P6.p descendants for the indicated genotypes. The number of animals scored is indicated above. (I) Number of cytoplasmic (pink), juxtamembrane (green), and combined total (yellow) LET-23::GFP foci. For statistical analysis, the average number of foci in the *rab-7(ok511)*, *dhc-1(vh22*), and *dhc-1(or195)* mutants was compared with wild type. The *dhc-1(vh22); rab-7(ok511)* double was compared with the *dhc-1(vh22)* mutant and was not significantly different from *rab-7(ok511).* (J) Total number of LET-23::GFP foci. All double mutants were compared with *lin-2(e1309)*. *dhc-1(vh22+RNAi); lin-2(-)* was not statistically different from *dhc-1(vh22); lin-2(-).* A two-tailed *t* test was used to calculate statistical significance (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\*\**p* \< 0.0001). Basal and apical membranes are facing in the same direction in all of the images and are indicated in A. Bar, 5 μm.](3771fig3){#F3}

In mammalian cell culture, Rab7 can recruit dynein to EGFR-containing late endosomes to traffic them along microtubules toward lysosomes in the perinuclear region ([@B19]). Therefore we tested whether the VPCs of *dhc-1(vh22)* mutants accumulated LET-23::GFP foci like *rab-7(ok511)* mutants. Similar to *rab-7(ok511)* animals, *dhc-1(vh22)* and *dhc-1(vh22); lin-2(e1309)* mutants accumulate LET-23::GFP foci in the P6.p daughter cells, P6.pa and P6.pp ([Figure 3, E, F, I, and J](#F3){ref-type="fig"}). The *dhc-1(vh22)* mutants accumulated less LET-23::GFP foci, which were primarily adjacent to, or appeared contiguous with, the plasma membrane compared with *rab-7(ok511)* mutants. The number of LET-23::GFP foci in *dhc-1(vh22); lin-2(e1309)* animals was not significantly enhanced by *dhc-1(RNAi)* ([Figure 3, H and J](#F3){ref-type="fig"}), and juxtamembrane LET-23::GFP foci were also seen in *dhc-1(or195)* mutants at 25°C ([Figure 3, G and I](#F3){ref-type="fig"}). Together these results suggest that DHC-1 might function at an earlier step of LET-23 trafficking than RAB-7. To test whether *dhc-1(vh22)* is epistatic to *rab-7(ok511)*, we constructed a *dhc-1(vh22); rab-7(ok511)* double mutant expressing LET-23::GFP. We found that *dhc-1(vh22)* did not suppress or enhance the *rab-7(ok511)* cytoplasmic vesicle phenotype ([Figure 3I](#F3){ref-type="fig"}). Although this does not preclude them from functioning in the same pathway, it suggests that *dhc-1* is not required for the *rab-7(ok511)* phenotype. We conclude that the suppression of the *lin-2(e1309)* Vul phenotype by *rab-7(ok511)* and *dhc-1(vh22)* mutations is likely due to a failure to efficiently down-regulate LET-23 EGFR via endosome/lysosome trafficking ([Figure 4](#F4){ref-type="fig"}).

![Model of LET-23 EGFR regulation by DHC-1 and RAB-7. DHC-1 (dynein) and RAB-7 promote endocytic trafficking of LET-23 EGFR to the lysosome for degradation. Our data suggest that dynein functions at an early step of receptor trafficking, moving endosomes along microtubules (MT) from the plasma membrane and toward the microtubule-organizing center (MTOC). Then, RAB-7 facilitates lysosomal degradation of LET-23 EGFR, which could also involve dynein. Disruption of either dynein or RAB-7 would result in accumulation of active LET-23 EGFR on endosomes, from which it can continue signaling.](3771fig4){#F4}

DISCUSSION
==========

Endosome trafficking and lysosome degradation of EGFR is an important mechanism for signal down-regulation. The late endosomal Rab7 GTPase couples with the dynein minus end--directed microtubule motor to traffic late endosomes to lysosomes and facilitate EGFR degradation ([@B19]). We previously identified RAB-7 as a potent negative regulator of LET-23 EGFR signaling during *C. elegans* vulva induction ([@B33]). Here we identified mutations in *dhc-1*, the dynein heavy chain, in a forward genetic screen for regulators of LET-23 EGFR signaling and intracellular trafficking. DHC-1 is a strong negative regulator of LET-23 EGFR signaling during *C. elegans* vulva induction. DHC-1 functions in the VPCs, the signal-receiving cells, and genetically functions at the level of LET-23 EGFR. Consistent with a role in EGFR trafficking, RAB-7 and DHC-1 are required for the proper localization of LET-23 EGFR in the VPCs. However, LET-23::GFP foci primarily accumulate adjacent to the plasma membrane in *dhc-1* mutant animals, whereas in *rab-7* mutants, LET-23::GFP foci are more numerous and distributed throughout the cytoplasm. Together these data suggest that DHC-1 is required for an early step in LET-23 EGFR trafficking to the lysosome in the VPCs and thus plays an important role in signal attenuation.

Cytoplasmic dynein is a heteromeric multiprotein minus end--directed microtubule motor, which is involved in a variety of cellular processes, ranging from movement of a multitude of cargo toward the nucleus to mitotic spindle assembly during mitosis ([@B29]). At the core of dynein complex is the DHC dimer, which contains a hexameric AAA+ (ATPase associated with various cellular activities) domain involved in ATP hydrolysis. Among the C-terminally located AAA+ domains lie the stalk and microtubule-binding domain. The N-terminal coiled-coil domains mediate dimerization, interactions with various intermediate, light, and light-intermediate chains, and interactions with LIS1 and the dynactin complex, which regulate cargo binding and motor activity ([@B1]). The *dhc-1(vh22)* allele has two missense mutations. One resides in the very C-terminus, a region specific to metazoan DHCs and of unknown function. The other missense mutation is in the microtubule-binding stalk and thus might alter the conformation of the stalk and potentially its interaction with microtubules. The previously identified conditional alleles of *dhc-1*---*or195* and *or352*---have been deemed strong alleles of *dhc-1* with respect to several embryonic defects ([@B14]; [@B31]). The *or195* allele also causes a defect in the microtubule-binding stalk, and the *or352* allele alters the second AAA+ domain ([@B27]). Surprisingly, these *dhc-1* alleles were less effective suppressors of *lin-2(e1309).* The *lin-2(e1309)* allele has often been used to facilitate the identification of embryonic lethal mutations ([@B23]) and was in the background for genetic screens that identified the *or195* and *or352* alleles, and thus there might have been a negative selection for alleles of *dhc-1* that suppress the *lin-2* Vul phenotype ([@B14]).

Dynein and the dynactin complex promote EGFR trafficking to the lysosome in mammalian cell culture ([@B40]). There are few data, however, for dynein regulating EGFR signaling. In HeLa cells, indirect inhibition of dynein via overexpression of the p50 dynamitin subunit of the dynactin complex inhibited EGFR degradation and caused sustained Erk1/2 activation ([@B40]). In *Drosophila melanogaster*, mutations in *dhc* and *p150 Glued* enhanced mutations in EGFR and Star, a regulator of Spitz ligand secretion, suggesting a positive role for dynein and the dynactin complex in Spitz-EGFR signaling ([@B18]). Our findings may be the first to demonstrate an in vivo role for dynein negatively regulating EGFR signaling and are congruent with the p50 dynamitin overexpression studies in HeLa cells. The differences between the *Drosophila* study and ours likely reflects the fact that dynein can regulate multiple trafficking pathways, and its effects on cell signaling are likely to be context dependent.

Rab7 recruits the dynein--dynactin complex to late endosomes to drive microtubule-based movement toward lysosomes ([@B19]). Because RAB-7 and DHC-1 both negatively regulate LET-23 EGFR signaling in the VPCs, we hypothesized that, as in HeLa cells, RAB-7 and DHC-1 function together to regulate LET-23 EGFR trafficking to the lysosome. We found that LET-23::GFP accumulated in foci adjacent to the plasma membrane of *dhc-1* mutants, which is again in line with EGFR localization in HeLa cells overexpressing p50 dynamitin. In *rab-7* mutants, LET-23::GFP accumulated in foci that are distributed throughout the cytoplasm. Both phenotypes are consistent with defective endosome-to-lysosome trafficking of LET-23 EGFR in *rab-7* and *dhc-1* mutants but are inconsistent with DHC-1 functioning exclusively with RAB-7. Instead, we propose that DHC-1/dynein is required at an earlier step of LET-23 EGFR trafficking, promoting movement of endosomes from the plasma membrane deeper into the cytoplasm, whereas RAB-7 regulates later steps of endosome trafficking ([Figure 4](#F4){ref-type="fig"}). The fact that *dhc-1* is not required for the *rab-7(ok511)* phenotype does not preclude it from functioning in the same pathway but might reflect that inhibition of *dhc-1* is incomplete or that additional motors or mechanisms might function in parallel with dynein to regulate early stages of LET-23 EGFR trafficking.

The LET-23::GFP localization phenotypes of *rab-7* and *dhc-1* mutants are more prominent in the P6.p daughters than in P6.p itself ([Figure 3](#F3){ref-type="fig"} and Supplemental Figure S1). We speculate that this could be cumulative and thus more apparent in the P6.p daughters. Alternatively, there could be increased LET-23 EGFR turnover in the P6.p daughters. LET-23 EGFR signaling in P6.p before the first cell division is sufficient for vulva induction ([@B24]; [@B2]). However, when inductive signaling is compromised, such as in a hypomorphic *lin-3 EGF* mutant, it is common to see hybrid fates in which only one of the two VPC daughters is induced, consistent with the P6.pa and P6.pp cells still being competent for induction ([@B42]). Therefore loss of *rab-7* or *dhc-1* could potentially increase signaling in P6.p and/or its daughters.

*dhc-1(vh22)* was identified with *agef-1(vh4)* as suppressors of the *lin-2(e1309)* Vul phenotype ([@B32]). We showed that *agef-1(vh4)* could partially restore LET-23::GFP localization to the basolateral membrane of *lin-2(e1309)* mutants, suggesting that AGEF-1 regulates apical versus basolateral distribution of LET-23 EGFR. Neither *dhc-1(vh22)* nor *rab-7(ok511)* visibly restored LET-23::GFP to the basolateral membrane of *lin-2(e1309)* mutants ([Figure 3, D and F](#F3){ref-type="fig"}), although we previously noted that the levels of LET-23::GFP required for induction are below detection ([@B32]). We suspect that mutations in *dhc-1* and *rab-7* may reduce turnover of active LET-23 EGFR that is present at low levels on the basolateral membrane of *lin-2/7/10* mutants and thus increase signaling above a threshold necessary for vulva induction.

In summary, we identify DHC-1, the core component of the dynein minus end--directed microtubule motor, as a potent negative regulator of LET-23 EGFR signaling in *C. elegans.* DHC-1 functions in the VPCs to promote an early step in the endocytic trafficking of LET-23 EGFR to the lysosome. This study highlights how alterations to basic cellular machinery such as vesicular trafficking and cytoskeletal transport can strongly affect signal transduction in vivo. In human cells, dynein could have a tumor-suppressive function via its role in endosome trafficking and attenuating signaling by EGFR or other receptors that regulate growth control.

MATERIALS AND METHODS
=====================

Strains and alleles
-------------------

General methods for the handling and culturing of *C. elegans* were as previously described ([@B8]). *C. elegans* Bristol strain N2 is the wild-type parent for all of the strains used in this study. *Escherichia coli* strain HB101 was used as a food source. The Hawaiian strain CB4856 was used for SNP mapping. Unless otherwise noted, experiments were performed at 20°C. Information on the genes and alleles used in this work can be found on WormBase (wormbase.org) and are available through *Caenorhabditis* Genetics Center ([cbs.umn.edu/cgc](http://cbs.umn.edu/cgc)) unless otherwise noted in the strain list (Supplemental Table S1).

Genetic mapping and cloning of *dhc-1(vh22*)
--------------------------------------------

SNP mapping was used to place *vh22* to the middle region of chromosome I ([@B9]). Chromosome mapping showed linkage of *vh22* to SNPs at −6 (W03D8), −1(D1007), 5 (B0205), 13 (F58D5), 14 (T06G6), and 26 (Y105E8B) mu. Interval mapping using two sets of recombinants, 127 animals in total, was conducted using the following SNPs, which result in a restriction fragment length polymorphism: Y71G12A at −17 mu (*Dra*I), W03D8 at −6 mu (*Dra*I), D1007 at −1 mu (*Dra*I), pkP1055 at 0 mu (*Ava*I), pkP1057 at 1 mu (*Nae*I), pkP1059 at 3 mu (*Dra*I), B0205 at 5 mu (*Dra*I), F58D5 at 13 mu (*Dra*I), T06G6 at 14 mu (*Dra*I), and Y105E8B at 25 mu (*Dra*I). Genomic DNA from QR180 *agef-1(vh4)* ([@B32]) and QR160 *dhc-1(vh22)* was isolated and submitted to Genome Quebec (Montreal, Canada) for Illumina sequencing. Within the defined map region, *dhc-1* (V3228D, D4344N), *elpc-1* (A629T), and *cpd-1* (T493I) carried homozygous nonsynonymous mutations unique to QR160 *dhc-1(vh22)* strain.

RNA interference
----------------

RNAi feeding was performed essentially as previously described ([@B22]) using the *dhc-1, elpc-1, cpd-1*, and *rab-7* clones from the Ahringer RNAi library (Geneservice, Cambridge, United Kingdom). Clones were verified by DNA sequencing. To avoid embryonic and larval lethal phenotypes, synchronized L1 larvae were placed on RNAi plates and scored for vulva induction when the animals reached L4 stage 36--48 h later.

Microscopy and phenotype analysis
---------------------------------

General methods for live-animal imaging using Nomarski differential interference contrast (DIC) microscopy were as previously described ([@B36]). Animals were analyzed on an Axio Zeiss A1 Imager compound microscope (Zeiss, Oberkochen, Germany), and images were captured using an Axio Cam MRm camera and AxioVision software (Zeiss). Muv and Vul phenotypes were scored by counting the vulval and nonvulval descendants of P3.p--P8.p in L4-stage larvae as described previously ([@B33]). Fisher's exact test ([graphpad.com/quickcalcs](http://graphpad.com/quickcalcs)) was used for statistical analysis of the vulval phenotypes. Confocal analysis was performed using Zeiss LSM510 and LSM780 laser scanning microscopes with 63× oil immersion lens (Zeiss) in a single-track mode using 488-nm excitation for GFP. Images were captured using ZEN 2009 and ZEN 2010 Image software (Zeiss). *zhIs038* transgene-carrying animals were visualized at the L3 larval stage. The number and location of LET-23::GFP-positive foci in the P6.p descendants were scored blindly.

The percentage embryonic lethality was determined by plating adult hermaphrodites, one per plate, and allowing them to lay eggs for several hours, after which, hermaphrodites were removed and the laid eggs were counted. Approximately 24 h later, the unhatched eggs were counted. To determine the percentage embryonic lethality for each strain, the number of unhatched eggs was divided by the total number of laid eggs.
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DHC

:   dynein heavy chain

EGFR

:   epidermal growth factor receptor

MAPK

:   mitogen-activated protein kinase

Muv

:   multivulva

VPC

:   vulval precursor cell

Vul

:   vulvaless.
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